Journal
MOLECULAR THERAPY
Volume 25, Issue 10, Pages 2404-2414Publisher
CELL PRESS
DOI: 10.1016/j.ymthe.2017.08.017
Keywords
-
Categories
Funding
- BBSRC CASE
- Lilly UK
- Parkinson's UK
- MRC
- Medical Research Council [MR/P007058/1] Funding Source: researchfish
- Parkinson's UK [J-1403, G-0915, K-1411] Funding Source: researchfish
- MRC [MR/P007058/1] Funding Source: UKRI
Ask authors/readers for more resources
Abnormal alpha-synuclein (alpha-synudein) expression and aggregation is a key characteristic of Parkinson's disease (PD). However, the exact mechanism(s) linking alpha-synudein to the other central feature of PD, dopaminergic neuron loss, remains unclear. Therefore, improved cell and in vivo models are needed to investigate the role of alpha-synudein in dopaminergic neuron loss. MicroRNA-7 (miR-7) regulates alpha-synudein expression by binding to the 3 ' UTR of the Synuclein Alpha Non A4 Component of Amyloid Precursor (SNCA) gene and inhibiting its translation. We show that miR-7 is decreased in the substantia nigra of patients with PD and, therefore, may play an essential role in the regulation of alpha-synudein expression. Furthermore, we have found that lentiviral-mediated expression of miR-7 complementary binding sites to stably induce a loss of miR-7 function results in an increase in alpha-synudein expression in vitro and in vivo. We have also shown that depletion of miR-7 using a miR-decoy produces a loss of nigral dopaminergic neurons accompanied by a reduction of striatal dopamine content. These data suggest that miR-7 has an important role in the regulation of alpha-synudein and dopamine physiology and may provide a new paradigm to study the pathology of PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available